Last kr82.50 DKK
Change Today -1.00 / -1.20%
Volume 85.1K
ZEAL On Other Exchanges
As of 11:02 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (ZEAL) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/23/14 - kr85.00
52 Week Low
12/27/13 - kr58.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZEALAND PHARMA A/S (ZEAL)

Related News

No related news articles were found.

zealand pharma a/s (ZEAL) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (ZEAL) Details

Zealand Pharma A/S, a biotechnology company, discovers and develops peptide drugs in Denmark. Its lead drug includes Lyxumia (lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company’s product pipeline also comprise Lantus and Lyxumia, which are in Phase III clinical trials for the treatment of type 2 diabetes; and ZP2929, a once-daily dual acting glucagon/GLP-1 peptide agonist that is in Phase I clinical trial for the treatment of diabetes and/or obesity. In addition, it develops danegaptide, a dipeptide gap junction modifier in Phase II clinical study with cardioprotective properties; ZP1480, an MSH melanocortin peptide agonist in Phase IIb clinical trial for the prevention of acute kidney injury following surgery; Elsiglutide, a GLP-2 peptide receptor agonist in Phase II clinical trial for the prevention of chemotherapy induced diarrhea; and ZP1848, a GLP-2 peptide agonist that has completed Phase Ib trial for the treatment of inflammatory bowel disease. Further, the company has peptide drug programs in various stages of pre-clinical development, primarily in the fields of cardio-metabolic diseases, diabetes, and obesity. Zealand Pharma A/S has collaboration agreements with Sanofi S.A.; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; Abbvie Inc.; and Eli Lilly. The company was founded in 1998 and is based in Copenhagen, Denmark.

104 Employees
Last Reported Date: 11/7/14
Founded in 1998

zealand pharma a/s (ZEAL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zealand pharma a/s (ZEAL) Key Developments

Zealand Pharma A/S Raises DKK 300 Million in Royalty Bond Financing

Zealand Pharma A/S announced that the company has raised USD 50 million/DKK 300 million in a non-dilutive, non-recourse bond structured financing backed by stand-alone lixisenatide (Lyxumia(r)) royalties. The Financing is provided by Athyrium Capital Management and its funds, a U.S.-based specialist healthcare investment manager. Credit Suisse acted as sole structuring advisor and placement agent in the transaction. The royalty bond carries an interest rate of 9.375% annually, and the combined annual payments of interest and principal are limited in recourse to 86.5% of Zealand's future annual revenue on lixisenatide as stand-alone product under its license agreement with Sanofi, until the bond is repaid in full. Potential future royalty revenue on LixiLan is not part of the Financing.

Zealand Pharma Mulls Acquisitions

Zealand Pharma A/S (CPSE:ZEAL), which has raised $ 50 million in a non-dilutive, non-recourse bond structured financing, is looking for acquisitions. The company indicated that as other potential sources of pipeline value growth, it is investigating clinical stage in-licensing and acquisition opportunities. Securing additional capital resources is key also for such transactions to move forward.

Zealand Pharma A/S Advances its Proprietary Stable Glucagon Analogue for Severe Hypoglycemia in Diabetes into Clinical Development

Zealand Pharma A/S announced that the company has dosed the first human subjects in a clinical Phase I trial with ZP4207, its novel stable glucagon analogue. The objectives of the trial are to evaluate the safety and human efficacy of ZP4207 as a novel approach to offer better and more convenient treatment of severe hypoglycemia. Severe hypoglycemia is an acute, life threatening condition resulting from a serious drop in blood sugar levels associated with insulin therapy in Type 1 and Type 2 diabetes patients. Glucagon is a native peptide, which plays an important role in the control of blood sugar levels. The effects of glucagon are opposite to those of insulin - it helps to release stored glucose and increase blood sugar levels. The therapeutic use of native glucagon in cases of hypoglycemia is made difficult by the peptide's very poor stability and low solubility. Current glucagon treatments are available in the form of lyophilized powder which requires reconstitution with sterile water in a multi-step process before use. In the case of an acute and severe hypoglycemia event, this can lead to handling errors, delay administration of glucagon and result in sub-optimal treatment. In preclinical studies, ZP4207 has demonstrated a strong stability profile and a good solubility, supporting the potential use of this glucagon analogue in a liquid dosage form as a ready-to-use rescue pen. Data from these studies suggest further that ZP4207 is comparable to native glucagon in its effect on releasing glucose stores into the blood stream to restore blood sugar levels, while being suitable for long term storage. Zealand currently retains all rights to ZP4207. In the first part of the Phase I clinical trial, conducted at a selected diabetes centre in Germany, Zealand expects to enroll up to 64 healthy volunteers who will be treated with single-ascending doses of ZP4207. The trial objectives are primarily to evaluate safety and tolerability and secondarily to evaluate various pharmacokinetic and pharmacodynamic measurements, as compared to native glucagon. In a second part of the trial, the same endpoints will be evaluated in 20 patients with Type 1 diabetes, who will be made hypoglycemic before treatment to get an indication of the efficacy of ZP4207 to release glucose stores and increase blood sugar levels in a cross-over design with native glucagon as active comparator. Zealand expects to complete the Phase I trial in first half of 2015 with results available mid 2015. The clinical development of ZP4207 as a better and more convenient treatment of severe episodes of hypoglycemia has the potential to follow an expedited plan, which could lead to first regulatory filing of this Zealand therapeutic as soon as early 2018.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEAL:DC kr82.50 DKK -1.00

ZEAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEAL.
View Industry Companies

Industry Analysis


Industry Average

Valuation ZEAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.9x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at